Natural Killer Cells in Older Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT00540956|
Recruitment Status : Completed
First Posted : October 8, 2007
Last Update Posted : May 16, 2011
RATIONALE: Studying natural killer cells in samples of blood from patients with cancer may help doctors find out how these cells are effected by chemotherapy.
PURPOSE: This clinical trial is studying natural killer cells in older patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Drug: cytarabine Other: laboratory biomarker analysis||Not Applicable|
- Determine the evolution of functional receptors of natural killer (NK) cells after completion of chemotherapy in elderly patients with acute myeloid leukemia in first remission.
- Measure the kinetics of cytotoxic functional recovery of NK cells.
- Determine activation markers of NK cells.
OUTLINE: This is a multicenter study.
Patients receive 1 course of consolidation therapy comprising an anthracycline and cytarabine to induce first remission.
Blood is collected on day 0 of the consolidation course and then every 2 weeks for 8 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Masking:||None (Open Label)|
|Official Title:||Descriptive Study Evaluating the Presence and Function of Natural Killer Cells in Elderly Patients With Acute Myeloid Leukemia in First Remission.|
|Study Start Date :||November 2006|
|Actual Primary Completion Date :||May 2011|
- Evolution of functional natural killer (NK) cells after chemotherapy
- Kinetics of NK cells
- Activation markers of NK cells
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00540956
|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes|
|Marseille, France, 13273|
|OverallOfficial:||Norbert Vey, MD||Institut Paoli-Calmettes|